Vertex Pharmaceuticals, Inc.

Jianglin Liang

David J Lauffer

Pan Li

Dean Shannon

Paul S Charifson

Francois Maltais

Mark Willem Ledeboer

Huai Gao

Emanuele Perola

Upul Keerthi Bandarage

John P Duffy

Brian Ledford

Joseph M Kennedy

Michael P Clark

Ioana Davies

Jun Feng

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders. 

Triazolothiadiazole inhibitor of c-Met protein kinase

Growing community of inventors

Needham, MA, United States of America

Jianglin Liang